Melanotan-II in hypoactive sexual desire and erectile dysfunction — evidence extract
No eligible study has been identified for Melanotan-II in hypoactive sexual desire and erectile dysfunction. The Institute records the question as not assessed and states what would change that.
§1Evidence extract: Hypoactive sexual desire and erectile dysfunction
§1.1Question and anchor outcome
- Population
- Persistently reduced sexual desire or impaired erectile function causing distress, assessed by validated instruments.
- Intervention
- Melanotan-II, subcutaneous in unregulated use
- Comparator
- As used in each contributing trial; reported per trial rather than pooled across comparator types
- Anchor outcome
- Female Sexual Function Index desire domain
Additional outcomes the Institute extracts for this indication: Female Sexual Distress Scale item 13; International Index of Erectile Function; Satisfying sexual events.
§1.2Contributing trials
No trial has been identified for Melanotan-II in hypoactive sexual desire and erectile dysfunction. No certainty rating is issued where that is so, for the reason given at §1.3.
§1.3Why no certainty rating is issued
The Institute rates certainty in a body of evidence. Where no eligible study has been identified there is no such body, and the domain-by-domain assessment used elsewhere in this series is not rendered: an inconsistency judgement requires two estimates to be inconsistent with one another, and an imprecision judgement requires an interval. Neither exists here.
The outcome is therefore recorded as not assessed. It is listed in the certainty index under that heading rather than at the lowest rating, because a rating of very low certainty says that evidence was found and is weak, and that is not what has happened.
What would change this: a controlled study in the population stated at §1.1, reporting the anchor outcome, retrievable in a form the Institute can appraise. The evidence gaps recorded in the monograph at §9 state what such a study would need to measure.
§1.4What this extract does not establish
References cited on this page
References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.
- Clayton AH, Althof SE, Kingsberg S, DeRogatis LR, Kroll R, Goldstein I, Kaminetsky J, Spana C, Lucas J, Jordan R, Portman DJ. Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial. Women’s Health 2016;12(3):325–337. doi:10.2217/whe-2016-0018 · PMID 27181790
- Carvalho M, Dinis-Oliveira RJ. Analytical and forensic aspects of counterfeit peptide hormones. Drug Testing and Analysis 2023;15(1):5–19. identifier not held by the Institute The digital object identifier previously carried on this record did not resolve and has been withdrawn. Journal and year are retained.
- Medicines and Healthcare products Regulatory Agency. Falsified Ozempic (semaglutide) pens: patient safety alert. MHRA Safety Alert 2023;Alert reference NatPSA/2023/012/MHRA. identifier not held by the Institute
Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.